Sarah Elizabeth Richards

More than half of patients with resected stage 3 melanoma with BRAF V600E or V600K mutations receiving a year’s worth of adjuvant dabrafenib and trametinib were still alive 5 years later.

Pooling data from physicians and patients appears to be an efficient way to answer urgent questions.

Some experts say the talc study’s data limitations weaken its impact in the field.

If crowdfunding doesn’t work, here’s how oncologists can help patients with financial toxicity.

As oncologists welcome new chronic lymphocytic leukemia treatments, one researcher creates a scoring system to make the case for transplants.